Project Grant R44AI186871
Award Date 9/10/25
Completion Date 8/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rockville, MD 20852, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, supports the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 variants and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to optimize the linkage...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $506,000 Project Grant titled "Development of siRNA-Peptide Libraries for Delivery Screening" to the Scripps Research Institute in California. This 2-year grant, running from Jul 9, 2025 to Jun 30, 2027, aims to develop high-throughput technologies for generating and screening siRNA-peptide conjugates to improve the delivery efficiency of small interfering RNA (siRNA) therapeutics. The goal is to address key...
- This $536,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify small molecule inhibitors against critical components of arenaviruses, which cause severe hemorrhagic fevers. The proposed studies aim to use machine learning and molecular screening to identify pan-reactive inhibitors targeting the arenavirus surface glycoprotein and RNA polymerase...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,163 Project Grant to Phase Genomics Inc. under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project aims to establish a novel antimicrobial approach that combines endolysin proteins from Phase Genomics' metagenomic database with self-replicating mRNA (repRNA) delivery using lipid nanoparticles. The Phase I proof-of-concept study has two key objectives: 1) evaluate whether...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $831,235 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Southern California (USC) to explore a key nucleotide synthesis enzyme as a potential target for developing broad-spectrum antiviral therapies. The project, led by Co-PIs Pinghui Feng and Chao Zhang, aims to genetically interrogate the enzyme's role in viral immune evasion and metabolic reprogramming...
- This $3,082,513 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to optimize a novel lipid prodrug delivery strategy for the antiviral drug remdesivir nucleoside monophosphate (RVN-MP) and other broad-spectrum nucleoside antivirals. The central objective is to enhance oral bioavailability, intracellular activation, and tissue delivery of these antivirals to improve their in...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $999,991 Project Grant to Tendel Therapies Inc. on August 13, 2025. The grant supports the development of an HIV reservoir-depletion agent, BSAB-98, a bispecific antibody that targets CCR5-expressing cells for elimination. Preclinical studies in infant rhesus macaques showed over 50% remission of simian immunodeficiency virus (SIV) after BSAB-98...